Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Completed 12Active not recruiting 4Terminated 3Withdrawn 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 23Lymphoma, Mantle-Cell 14Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 5Waldenstrom Macroglobulinemia 4Lymphoma, B-Cell 4Lymphoma 4Leukemia, B-Cell 4Leukemia 3Neoplasms 2Melanoma 2Leukemia, Prolymphocytic 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurologic Manifestations 1Myeloproliferative Disorders 1Lymphoma, AIDS-Related 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Lymphoid 1Leukemia, Hairy Cell 1Hematologic Diseases 1Graft vs Host Disease 1Glioblastoma 1Disease Progression 1Central Nervous System Neoplasms 1Cardiovascular Diseases 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Rituximab 16Cyclophosphamide 16Prednisone 7Doxorubicin 7pirtobrutinib 6fludarabine 6Vincristine 6Lenalidomide 6venetoclax 5pembrolizumab 5fludarabine phosphate 5Etoposide 5Bendamustine Hydrochloride 5ibrutinib 4acalabrutinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Dexamethasone 4CT-P10 4polatuzumab vedotin 3etoposide phosphate 3Immunotherapy, Adoptive 3tazemetostat 2liposomal doxorubicin 2Nivolumab 2Injections 2Ifosfamide 2Gemcitabine 2Cisplatin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell × ibrutinib × Clear all
NCT04662255 2026-05-15

BRUIN-MCL-321

Eli Lilly and Company

Phase 3 Active not recruiting
500 enrolled
Lymphoid

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03478514 2026-04-09

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

Alliance Foundation Trials, LLC.

Phase 2 Active not recruiting
39 enrolled
Lymphoid

Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT03229200 2025-10-30

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Pharmacyclics Switzerland GmbH

Phase 4 Active not recruiting
297 enrolled
LymphoidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

NCT04234061 2024-11-07

TARMAC

Peter MacCallum Cancer Centre, Australia

Phase 2 Active not recruiting
20 enrolled
Lymphoid

Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡